Is Kevzara Approved for PMR?
No, Kevzara (sarilumab) is not FDA-approved for polymyalgia rheumatica (PMR). It is approved for moderately to severely active rheumatoid arthritis (RA) in adults who have not responded adequately to one or more disease-modifying antirheumatic drugs (DMARDs), either alone or combined with methotrexate.[1]
Is Kevzara Used Off-Label for PMR?
Kevzara sees limited off-label use for PMR, though some small studies and case reports explore it in refractory cases. PMR standard treatment starts with low-dose glucocorticoids like prednisone; for relapsing or steroid-dependent patients, options include methotrexate or tocilizumab (Actemra). Sarilumab, an IL-6 receptor blocker like tocilizumab, showed promise in a 2022 phase 3 trial subset for giant cell arteritis (GCA, often linked to PMR), reducing steroid needs.[2] A 2023 case series reported success in five steroid-refractory PMR patients, with rapid symptom relief and taper feasibility.[3] However, no large PMR-specific trials exist, and rheumatologists rarely choose it first-line due to cost and infection risks.
How Does Kevzara Compare to PMR Treatments?
| Treatment | Mechanism | PMR Role | Key Differences from Kevzara |
|-----------|-----------|----------|------------------------------|
| Prednisone | Glucocorticoid | First-line (10-20 mg/day) | Cheaper, faster onset; higher long-term risks like osteoporosis. Kevzara allows steroid sparing.[1] |
| Methotrexate | Immunosuppressant | Steroid-sparing add-on | Oral, lower cost (~$50/month); less effective in some trials vs. IL-6 blockers. |
| Tocilizumab (Actemra) | IL-6 blocker | GCA-approved; off-label PMR | Similar to Kevzara but more PMR/GCA data; subcutaneous or IV. Kevzara is subcutaneous only.[2] |
| Sarilumab (Kevzara) | IL-6 blocker | Off-label RA biologic | RA-approved; PMR evidence anecdotal. Higher upper respiratory infection risk (12% vs. 6% placebo).[1] |
IL-6 inhibitors like Kevzara target inflammation driving PMR symptoms (shoulder/hip pain, morning stiffness), but lack PMR guideline endorsement from ACR/EULAR.
What Are the Risks and Costs for PMR Use?
Kevzara carries black-box warnings for serious infections, gastrointestinal perforations, and lab abnormalities (e.g., neutropenia). In RA trials, infections hit 48% of users vs. 40% placebo; PMR patients (often elderly) face amplified risks.[1] No PMR-specific safety data exists.
US list price: ~$4,200 per 200 mg monthly dose (two injections); patient assistance cuts copays to $0-$5 via Sanofi/Regeneron programs.[4] Patents on sarilumab expire around 2032 in major markets.[5]
When Might Doctors Consider Kevzara for PMR?
In steroid-intolerant or relapsing PMR with GCA overlap, after failing methotrexate. Consult rheumatology; monitor CRP/ESR and infections closely. Ongoing trials (e.g., NCT03688270) test IL-6 blockers in PMR, potentially expanding use.[2]
[1]: FDA Kevzara Label
[2]: Ann Rheum Dis 2022;81:621-631
[3]: Rheumatol Int 2023;43:123-127
[4]: GoodRx Kevzara Pricing
[5]: DrugPatentWatch: Sarilumab